Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.00 0.00%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to 30 September 2026

Free cash flow was −$1.5M: capital expenditures were more than operating cash flow. Cash rose by $2.4M. Lines the picture does not name came to +$2.7M. What is a cash flow statement?

Free cash flow
−$1.5M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$2.4M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
From investments, net0.0
Other0.0
Change in cash0.0

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 From the 10-Q filed 13 Nov Jun '26 Mar '26 Dec '25 Older periods
Net Income
(1.36) (2.12) (1.95) (1.57)

+8 more quarters

Depreciation & Amortization
(0.01) 0.00 0.00 0.01
Non Cash Items (Other)
— 0.15 0.13 0.20
Accounts Receivable Change
(0.21) (0.31) 0.11 (0.17)
Accounts Payable Change
0.68 (0.25) 0.22 (0.37)
Change in payables and accrued liability
— 0.50 0.10 (0.39)
Change in other assets and liabilities
— 0.21 (0.58) 0.51
Operating Cash Flow
(1.48) (1.82) (1.96) (1.77)
Short Term Investments Change (Net)
1.15 (0.36) 1.27 0.47
Investing cash flow
1.15 (0.36) 1.27 0.47
Equity Repurchase (Common, Net)
— — — 0.00
Financing cash flow
— — — 0.00
Exchange Rate Adjustment
0.00 0.00 0.00 0.00
Change in Cash
2.41 (2.17) (0.70) (1.30)
Beginning Cash
— 0.00 5.85 0.00
Ending Cash
2.41 (2.17) 5.16 (1.30)
Stock Based Compensation
0.14 0.14 0.14 0.19
Dividends Paid (Common)
— 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
— 0.15 (0.14) (0.42)
Investments Change (Net)
1.15 (0.36) 1.27 0.47
Issuance/Purchase of Shares
— — — 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 13 Nov 2026